— Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year. — Revenues were EUR2.1 million, vs. EUR0.3 million reported last year. — Research & development expenses were EUR11.7 million compared to EUR9.8 million last year. — Cash, cash equivalents and current financial assets totaled EUR76.5 million as […]
— Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year. — Revenues were EUR2.1 million, vs. EUR0.3 million reported last year. — Research & development expenses were EUR11.7 million compared to EUR9.8 million last year. — Cash, cash equivalents and current financial assets totaled EUR76.5 million as […]
— Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year.
— Revenues were EUR2.1 million, vs. EUR0.3 million reported last year.
— Research & development expenses were EUR11.7 million compared to EUR9.8 million last year.
— Cash, cash equivalents and current financial assets totaled EUR76.5 million as of September 30, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
